SUN Farmaceutica DO Brasil Ltda Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: SUN Farmaceutica DO Brasil Ltda Pharmaceutical Import Records from India — 3 Products, $800.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Farmaceutica DO Brasil Ltda — Pharmaceutical Importer Profile (2026) | 3 Products, $800.0K Trade | TransData Nexus

SUN Farmaceutica DO Brasil Ltda

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $800.0K Total Trade · DGFT Verified

SUN Farmaceutica DO Brasil Ltda is a pharmaceutical importer based in Brazil with a total trade value of $800.0K across 3 products in 1 therapeutic categories. Based on 16 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SUN Farmaceutica DO Brasil Ltda sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

SUN Farmaceutica DO Brasil Ltda — Import Portfolio & Supplier Network

SUN Farmaceutica DO Brasil Ltda import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SUN Farmaceutica DO Brasil Ltda?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$3.9M	111	100.0%

SUN Farmaceutica DO Brasil Ltda sources from 1 verified Indian supplier across 73 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Abiraterone tablets USP 250MG Each	$350.0K	7
Anya tablets USP 1MG ( anastrazole)	$200.0K	4
Capecitabina 500MG tablets Each	$200.0K	4
Nidhi cap 150MG Each capsule contains	$200.0K	4
Anya USP TAB 1MG 3x10b br Each tablet contains: anastrozole (Pack:03x10)	$150.0K	3
Anya tablets USP 1MG (anastrozole)	$100.0K	2
Capecitabina 500MG tablets Pack	$100.0K	2
Capecitabina 500MG tablets	$100.0K	2
Octride 100 INJ. (octreotide injection	$100.0K	2
Temozolomida 20 MG capsula Each	$100.0K	2
Temozolomida 100 MG capsula Each	$100.0K	2
Pantasun i v INJ pantoprazole Pack	$100.0K	2
Abiraterone tablets USP 250MG (abiraterone acetate tablets USP 250MG) [3289 packx 120's] (batch no. hag0244a, hag0245a	$100.0K	2
Octride 100 INJ. (octreotide injection 100mcg/ML) (Pack:05x01)	$100.0K	2
Anya tablets USP 1 MG (anastrozole)	$98.5K	2

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bortezomib	Advanced Oncology	$300.0K	6	1.4%	15
2	Sunitinib	Advanced Oncology	$300.0K	6	0.5%	13
3	Anastrozole	Advanced Oncology	$200.0K	4	0.2%	13

SUN Farmaceutica DO Brasil Ltda imports 3 pharmaceutical products across 1 categories into Brazil totaling $800.0K.

SUN Farmaceutica DO Brasil Ltda — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SUN Farmaceutica do Brasil Ltda is a Brazilian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on August 13, 2021, the company operates under the legal entity CNPJ 05.035.244/0003-95, with its headquarters located at Rua Francisco de S e Melo, 00252, GLP 1 Armazem 11, Cordovil, Rio de Janeiro, RJ, 21010-410. (cnpj.biz)

As a subsidiary of Sun Pharmaceutical Industries Limited, SUN Farmaceutica do Brasil Ltda plays a pivotal role in the Brazilian pharmaceutical distribution network. The company's primary activity, as classified under the National Classification of Economic Activities (CNAE) code 46.44-3-01, is the wholesale trade of human medicines and drugs. (cnpj.biz)

2Distribution Network

SUN Farmaceutica do Brasil Ltda maintains a strategic distribution network with facilities in Rio de Janeiro and Goiânia, Goiás. The Rio de Janeiro facility, located at Rua Francisco de S e Melo, 00252, GLP 1 Armazem 11, Cordovil, serves as a key hub for operations. (cnpj.biz) The Goiânia facility, situated at Rodovia Go080, S/N, Km 02 Quadrach Lote 1 e 2, Faz Planicie, functions as the company's main office. (infoinvest.com.br)

While specific details regarding the company's logistics capabilities and geographic coverage beyond these locations are not publicly disclosed, the presence of facilities in both Rio de Janeiro and Goiás suggests a focus on serving the southeastern and central regions of Brazil. This strategic positioning likely enables efficient distribution to various parts of the country.

3Industry Role

In Brazil's pharmaceutical supply chain, SUN Farmaceutica do Brasil Ltda operates as a primary wholesaler, importing and distributing finished pharmaceutical formulations. The company's focus on finished products, rather than raw active pharmaceutical ingredients (APIs), indicates a strategic approach to meet the market demand for ready-to-use medications. By sourcing these products from its parent company, Sun Pharmaceutical Industries Limited, SUN Farmaceutica do Brasil Ltda ensures a consistent supply of high-quality pharmaceuticals to the Brazilian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SUN Farmaceutica DO Brasil Ltda

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

SUN Farmaceutica do Brasil Ltda's sourcing strategy exhibits a high degree of concentration, with all 16 shipments from India originating from a single supplier: Sun Pharmaceutical Industries Limited. This exclusive sourcing relationship accounts for a total import value of $800,000 USD, with the top three products—Bortezomib, Sunitinib, and Anastrozole—each valued at $300,000 USD and $200,000 USD, respectively. The portfolio concentration is notable, with these three products representing 100% of the company's imports from India.

This single-source dependency may present both strategic advantages and risks. On one hand, it allows for streamlined procurement processes and potentially favorable terms due to the volume of business. On the other hand, reliance on a single supplier could expose the company to supply chain disruptions in the event of issues such as production delays, regulatory challenges, or geopolitical tensions affecting trade routes. The absence of alternative suppliers in the current sourcing strategy suggests a need for diversification to mitigate potential risks.

2Supply Chain Resilience

The resilience of SUN Farmaceutica do Brasil Ltda's supply chain is closely tied to its exclusive sourcing arrangement with Sun Pharmaceutical Industries Limited. While this relationship ensures a consistent supply of finished pharmaceutical formulations, the lack of backup suppliers introduces vulnerabilities. In the event of disruptions affecting Sun Pharmaceutical Industries Limited, such as production issues or regulatory challenges, SUN Farmaceutica do Brasil Ltda may face challenges in maintaining its product supply.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the regulation of pharmaceutical products is overseen by the Brazilian Health Regulatory Agency, known as Anvisa (Agência Nacional de Vigilância Sanitária). Anvisa is responsible for ensuring the safety, efficacy, and quality of health-related products and services, including the authorization of clinical trials, marketing authorization of drugs and biological products, and post-marketing surveillance. (gov.br)

The regulatory framework governing pharmaceutical imports into Brazil is comprehensive, encompassing various categories of drugs such as new synthetic and semi-synthetic drugs, generic drugs, similar drugs (branded generics), and over-the-counter (OTC) drugs. Each category has specific requirements for registration, quality standards, and labeling to ensure compliance with Brazilian health regulations. (gov.br)

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in Brazil are stringent, with Anvisa mandating that all imported drugs undergo a registration process to verify their compliance with Brazilian health standards. This process includes the submission of detailed documentation, such as clinical trial data, manufacturing processes, and quality control measures. Additionally, Good Manufacturing Practice (GMP) certification is a prerequisite for the importation of pharmaceutical products. Anvisa recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from these recognized organizations to facilitate the import process. (gov.br)

SUN Farmaceutica DO Brasil Ltda — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

SUN Farmaceutica do Brasil Ltda's product strategy focuses exclusively on the Advanced Oncology therapeutic category, importing finished pharmaceutical formulations such as Bortezomib, Sunitinib, and Anastrozole. This concentrated approach suggests a strategic decision to specialize in oncology treatments, potentially leveraging market demand and expertise in this therapeutic area. The choice to import these specific products may be driven by factors such as high unmet medical needs, favorable market conditions, and the company's alignment with its parent company's product portfolio. By focusing on a niche segment, SUN Farmaceutica do Brasil Ltda can position itself as a specialized distributor, offering targeted solutions to healthcare providers and patients in Brazil.

2Sourcing Profile

SUN Farmaceutica do Brasil Ltda's sourcing strategy is characterized by a strong reliance on its parent company, Sun Pharmaceutical Industries Limited, for the supply of finished pharmaceutical formulations. This approach ensures consistency in product quality

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — SUN Farmaceutica DO Brasil Ltda

What products does SUN Farmaceutica DO Brasil Ltda import from India?

SUN Farmaceutica DO Brasil Ltda imports 3 pharmaceutical products across 1 categories. Top imports: Bortezomib ($300.0K), Sunitinib ($300.0K), Anastrozole ($200.0K).

Who supplies pharmaceuticals to SUN Farmaceutica DO Brasil Ltda from India?

SUN Farmaceutica DO Brasil Ltda sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $3.9M).

What is SUN Farmaceutica DO Brasil Ltda's total pharmaceutical import value?

SUN Farmaceutica DO Brasil Ltda's total pharmaceutical import value from India is $800.0K, based on 16 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SUN Farmaceutica DO Brasil Ltda focus on?

SUN Farmaceutica DO Brasil Ltda imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full SUN Farmaceutica DO Brasil Ltda Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

SUN Farmaceutica DO Brasil Ltda

SUN Farmaceutica DO Brasil Ltda — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to SUN Farmaceutica DO Brasil Ltda?

What Formulations Does SUN Farmaceutica DO Brasil Ltda Import?

What Products Does SUN Farmaceutica DO Brasil Ltda Import?

Top Products by Import Value

SUN Farmaceutica DO Brasil Ltda Therapeutic Categories — 1 Specializations